Amicus Therapeutics (FOLD) Upgraded by Zacks Investment Research to “Hold”
Zacks Investment Research upgraded shares of Amicus Therapeutics (NASDAQ:FOLD) from a strong sell rating to a hold rating in a report published on Wednesday.
According to Zacks, “AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. “
Several other equities research analysts have also commented on FOLD. BidaskClub upgraded shares of Amicus Therapeutics from a hold rating to a buy rating in a research note on Monday. Cowen reiterated a buy rating and set a $22.00 price objective on shares of Amicus Therapeutics in a research note on Wednesday, January 10th. Robert W. Baird reiterated an outperform rating and set a $18.00 price objective (up previously from $16.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Chardan Capital reiterated a buy rating and set a $18.50 price objective (up previously from $16.50) on shares of Amicus Therapeutics in a research note on Thursday, October 5th. Finally, Leerink Swann reiterated a buy rating and set a $20.00 price objective (up previously from $17.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Amicus Therapeutics has an average rating of Buy and an average price target of $18.31.
Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The firm had revenue of $10.90 million during the quarter, compared to analyst estimates of $9.02 million. During the same quarter in the previous year, the business posted ($0.33) EPS. Amicus Therapeutics’s revenue for the quarter was up 419.0% compared to the same quarter last year. sell-side analysts anticipate that Amicus Therapeutics will post -1.52 EPS for the current fiscal year.
In related news, insider Jay Barth sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $14.71, for a total transaction of $73,550.00. Following the completion of the sale, the insider now directly owns 69,184 shares in the company, valued at $1,017,696.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Daphne Quimi sold 8,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $14.72, for a total transaction of $117,760.00. Following the sale, the senior vice president now owns 62,676 shares of the company’s stock, valued at $922,590.72. The disclosure for this sale can be found here. Insiders have sold 197,890 shares of company stock worth $2,767,181 in the last quarter. Company insiders own 3.40% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. Schwab Charles Investment Management Inc. boosted its holdings in Amicus Therapeutics by 4.4% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 763,775 shares of the biopharmaceutical company’s stock worth $10,991,000 after buying an additional 31,900 shares in the last quarter. Sage Capital Advisors llc bought a new stake in Amicus Therapeutics during the third quarter worth approximately $154,000. GSA Capital Partners LLP bought a new stake in Amicus Therapeutics during the third quarter worth approximately $309,000. Iguana Healthcare Management LLC bought a new stake in Amicus Therapeutics during the third quarter worth approximately $905,000. Finally, Sterling Capital Management LLC bought a new stake in Amicus Therapeutics during the third quarter worth approximately $218,000.
ILLEGAL ACTIVITY NOTICE: “Amicus Therapeutics (FOLD) Upgraded by Zacks Investment Research to “Hold”” was first reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/amicus-therapeutics-fold-upgraded-by-zacks-investment-research-to-hold/1812803.html.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.